Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PlasmaCap IG
- Development stage
- Unknown
- Lead developer
- Evolve Biologics
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
**PlasmaCap IG** is a 10% liquid formulation of intravenous immunoglobulin (IVIG) manufactured using Evolve Biologics' proprietary **PlasmaCap EBA** technology, which employs expanded bed adsorption chromatography with affinity adsorbents to efficiently capture immunoglobulin from human plasma without ethanol precipitation, yielding higher purity and efficiency. Developed by Evolve Biologics as an investigational replacement therapy, it provides passive immunity through polyclonal antibodies for adult and pediatric patients with **primary immunodeficiency disease (PIDD)**, demonstrated efficacy in Phase III trials by reducing acute serious bacterial infections below one per patient-year while showing favorable safety and tolerability.[1][3][7][11]
- Brand names
- PlasmaCap IG
- Other names
- 10% intravenous immunoglobulin - Evolve Biologics10% IVIG - Evolve BiologicsHuman Immunoglobulin - Evolve BiologicsIntravenous immunoglobulin - Evolve Biologics
Beyond the preview
Go deeper on PlasmaCap IG.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PlasmaCap IG.